Oncology News

The FDA has issued orphan drug designation to CX-4945 for the treatment of cholangiocarcinoma, which will expedite its development, the manufacturer announced.

The FDA granted priority review to regorafenib tablets as a second-line systemic treatment for patients with hepatocellular carcinoma, according to the drug’s manufacturer.

In 2015, hepatocellular carcinoma was the most common indication for liver transplantation in the U.S., yet the likelihood of receiving a transplantation decreased the most among waitlist registrants with this cancer, according to recent study data.

Although the incidence of hepatocellular carcinoma continued to rise, researchers discovered the rate of increase slowed between 2010 and 2012, except among high risk subgroups in certain geographic regions.

In a phase 2 clinical trial, the use of yttrium-90 radioembolization was more effective in prolonging time to tumor progression vs. conventional transarterial chemoembolization in patients with early intermediate hepatocellular carcinoma.

Medicare beneficiaries who are diagnosed with cancer and are without supplemental health insurance incurred out-of-pocket expenses of nearly a quarter of their household income, according to a national survey-based study published in JAMA Oncology.

Researchers found through long-term follow-up that patients with hepatitis C virus infection who achieved sustained virologic response after interferon-based therapy were still at risk for hepatocellular carcinoma, more specifically older patients and those with cirrhosis.

SuperSonic Imagine announced the FDA granted 510(k) clearance to add additional imaging probes — for liver disease and breast lesions — for use with its Aixplorer platform.

Mail outreach strategies were effective for increasing screening rates for hepatocellular carcinoma among patients with cirrhosis, a population most at-risk, according to data from a recent prospective study.

BOSTON — Opdivo monotherapy was safe and effective in patients with advanced hepatocellular carcinoma, irrespective of infection status, according to results of the CheckMate 040 trial presented during a Late Breaker at The Liver Meeting 2016.